Findings

What do systematic reviews say?

9 questions · 9 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 0 · 0%Moderate 6 · 66.7%High 2 · 22.2%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- TDF vs placebo · HIV infection
  Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals 2012 · Cochrane Headline outcomes only
  RR 0.33 [0.2, 0.55]
  2 studies · 4027 participants
  Moderate
Direct match · question page
- TDF vs AZT · Virologic response
  Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 2.04 [0.17, 24.84]
  2 studies · 586 participants
  High
Direct match · question page
- TDF vs AZT · Serious adverse events
  Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 0.92 [0.6, 1.43]
  2 studies · 586 participants
  High
Direct match · question page
- TDF vs AZT · Adherence/tolerability/retention
  Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 1.17 [1.06, 1.29]
  2 studies · 586 participants
  Moderate
Direct match · question page
- TDF+ FTC vs placebo · HIV infection
  Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals 2012 · Cochrane Headline outcomes only
  RR 0.49 [0.28, 0.85]
  4 studies · 8813 participants
  Moderate

TDF vs placebo

HIV infection · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)

TDF probably leads to lower HIV infection compared with placebo (moderate certainty).

1 finding from 1 review

Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals 2012 · Cochrane Headline outcomes only
RR 0.33 [0.2, 0.55]
2 studies · 4027 participants
Moderate

TDF vs placebo

Serious adverse events · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)

TDF showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals 2012 · Cochrane Headline outcomes only
RR 1.03 [0.79, 1.33]
1 study · 3168 participants
Moderate

TDF vs AZT

Serious adverse events · patients with initial ART

TDF showed no clear difference in serious adverse events compared with AZT (high certainty).

1 finding from 1 review

Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
RR 0.92 [0.6, 1.43]
2 studies · 586 participants
High

TDF vs AZT

Virologic response · patients with initial ART

TDF showed no clear difference in virologic response compared with AZT (high certainty).

1 finding from 1 review

Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
RR 2.04 [0.17, 24.84]
2 studies · 586 participants
High

TDF vs AZT

Adherence/tolerability/retention · patients with initial ART

TDF probably leads to higher adherence/tolerability/retention compared with AZT (moderate certainty).

1 finding from 1 review

Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
RR 1.17 [1.06, 1.29]
2 studies · 586 participants
Moderate

TDF vs AZT

Immunological response · patients with initial ART

1 finding from 1 review

Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 515 participants
Moderate

TDF vs AZT

Drug resistance · patients with initial ART

It is very uncertain whether TDF changes drug resistance compared with AZT (very low certainty).

1 finding from 1 review

Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
RR 20.43 [1.24, 335.9]
1 study · 71 participants
Very low

TDF+ FTC vs placebo

HIV infection · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)

TDF+ FTC probably leads to lower HIV infection compared with placebo (moderate certainty).

1 finding from 1 review

Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals 2012 · Cochrane Headline outcomes only
RR 0.49 [0.28, 0.85]
4 studies · 8813 participants
Moderate

TDF+ FTC vs placebo

Serious adverse events · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)

TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals 2012 · Cochrane Headline outcomes only
RR 1 [0.83, 1.19]
3 studies · 6862 participants
Moderate